SLC5A2 and heart failure: This comprehensive review underscores the transformative impact of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin, in the management of heart failure across its diverse phenotypes, including chronic, acute, post-myocardial infarction, and preserved or mildly reduced ejection fraction subgroups.